Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

MLA

Chiun-Sheng Huang, et al. “Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.” Journal of Clinical Oncology, vol. 34, Apr. 2016, pp. 1034–42. EBSCOhost, https://doi.org/10.1200/jco.2015.62.1797.

APA

Chiun-Sheng Huang, Christian Jackisch, Michael Untch, A Armour, David W. Hillman, Jo Anne Zujewski, Eleanor McFadden, Stella Dolci, Véronique Diéras, Jośe Baselga, Amylou C. Dueck, Sergei Tjulandin, Edith A. Perez, Antonio C. Wolff, Holger Eidtmann, Frances M. Boyle, Young-Hyuck Im, Kathleen I. Pritchard, Ian E. Smith, … Phuong Dinh. (2016). Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology, 34, 1034–1042. https://doi.org/10.1200/jco.2015.62.1797

Chicago

Chiun-Sheng Huang, Christian Jackisch, Michael Untch, A Armour, David W. Hillman, Jo Anne Zujewski, Eleanor McFadden, et al. 2016. “Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.” Journal of Clinical Oncology 34 (April): 1034–42. doi:10.1200/jco.2015.62.1797.